Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 27

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 27
---
2024 Pre-Funded Warrants”) and one warrant identical
to the January 2024 Warrants included in the units. The January 2024 Pre-Funded Warrants have an exercise price of $0.60 per share and
were immediately exercisable until exercised in full. The January 2024 Warrants have an exercise price of $25.41 per share, were immediately
exercisable upon issuance, and expire on January 31, 2029. The January 2024 Offering closed on January 31, 2024, generating net proceeds
to the Company of approximately $1.9 million, after deducting underwriting discounts and commissions and the payment of other offering
expenses payable by the Company of approximately $510,000.

The Company granted WallachBeth Capital LLC a
45-day over-allotment option to purchase additional shares of common stock, additional January 2024 Warrants, or additional January 2024
Pre-Funded Warrants, or any combination thereof. WallachBeth Capital LLC partially exercised its over-allotment option with respect to
13,637 January 2024 Warrants on January 31, 2024, and an additional one share of common stock and one January 2024 Warrant on February
14, 2024.

The Company also issued to WallachBeth Capital
LLC warrants (the “January 2024 Representative Warrants”) to purchase 6,260 shares of the Company’s common stock at
an exercise price of $25.41 per share. The January 2024 Representative Warrants were immediately exercisable beginning on January 31,
2024 until January 31, 2029.

16

Warrant Exercises

During the three months ended March 31, 2025,
the Company issued 385,200 shares of common stock upon the exercise of 385,200 pre-funded warrants issued in September 2024, resulting
in proceeds to the Company of $1,926. During the three months ended March 31, 2024, the Company issued 8,326 shares of common stock upon
the exercise of 8,326 January 2024 Pre-Funded Warrants, resulting in proceeds to the Company of $4,995.

Common Stock Warrants

As of March 31, 2025, the Company accounts for
all issued and outstanding warrants to purchase common stock as equity-classified instruments based on the guidance in ASC 480 and ASC
815.

The following table presents